<DOC>
	<DOCNO>NCT00367965</DOCNO>
	<brief_summary>To demonstrate subjective sleep efficacy eszopiclone 3 mg subject insomnia relate rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Study Eszopiclone Compared Placebo Daytime Function Subjects With Insomnia Related Rheumatoid Arthritis</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , placebo control , parallel group study eszopiclone 3 mg subject insomnia relate rheumatoid arthritis . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Inclusion Criteria Subject must understand purpose study willing adhere study schedule procedure describe protocol . Subject must 2564 year age ( inclusive ) day sign consent . Subject must diagnose rheumatoid arthritis defined American College Rheumatology . Subject must stable regimen treatment rheumatoid arthritis minimum 90 day prior study start . Subject must report wake time sleep onset ( WASO ) great equal 45 minute less equal 6.5 hour total sleep time least three time week previous month symptom insomnia must post date onset rheumatoid arthritis . Subject physical exam must show clinically significant abnormal finding ( relate rheumatoid arthritis ) screening . Subject must clinically significant abnormal laboratory finding screen ( relate rheumatoid arthritis ) . Subject must clinically significant ECG abnormality screen . Exclusion Criteria Subject diagnosis fibromyalgia , juvenile rheumatoid arthritis . Subject history circadian rhythm disorder , travel across &gt; 3 time zone regular basis . Female subject pregnant , lactate within 6months post partum . Subject history drug alcohol abuse dependence past 2 year positive urine drug test screening . Subject clinically significant unstable medical abnormality unstable chronic disease ( insomnia rheumatoid arthritis ) include severe cardiac , renal , hepatic respiratory disease , seizure disorder . Subject participate investigational drug study within 30 day prior screen plan participate investigational drug study participation study . Subject history malignancy within 5 year , current malignancy , except nonmelanoma skin cancer . Subject current primary psychiatric diagnosis follow disorder : dementia , delirium , schizophrenia , psychosis , psychotic disorder , dysthymic disorder ; major depressive disorder , bipolar disorder ; cyclothymic disorder , mood disorder , primary anxiety disorder , primary panic disorder , nocturnal panic disorder . Subject follow Personality Disorders diagnose : schizotypal , schizoid , borderline personality disorder ; personality disorder would compromise investigator 's ability evaluate safety efficacy study medication . Subject difficulty sleep initiation maintenance associate know medical diagnosis [ e.g . sleep apnea ] ; diagnose untreated restless leg syndrome ( RLS ) periodic leg movement syndrome ( PLMS ) . Subject used drug know suspected affect hepatic renal clearance capacity within period 30 day prior screen . Subject report consumption two alcoholic beverage daily , 14 alcoholic beverage weekly , five alcoholic beverage give day . Subject rotate third/night shift worker . Subject staff member relative staff member .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Insomnia relate rheumatoid arthritis ( RA )</keyword>
</DOC>